Innate Pharma SA today announces results for its Phase IIa study with IPH 1101, an agonist of gamma delta T cells, as a second line monotherapy in metastatic renal cell carcinoma.
In connection with this announcement, a conference call was organized on May 23, 2008.   

The slideshow is available here: